"FDA approval of BioIntelliSense’s patient monitoring system signals major progress in remote patient monitoring market" was ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Boston Scientific ( (BSX) ) just unveiled an announcement. Boston Scientific Corporation has announced the resumption of its AVANT GUARD ...

Late last month, Boston Scientific announced it was pausing ... to continue was made in conjunction with the trial’s data monitoring committee. In an interview with Fierce Medtech following ...

Angelo Auricchio, chief medical officer for Rhythm Management at Boston Scientific in Europe, Middle East and Africa (EMEA). “Remotely monitoring worsening heart failure can also reduce ...

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.